| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Regaloside C targets multiple molecular pathways involved in inflammation and cellular protection, including TNF-α, MMP-2, ERα, AKT1, TLR4, and HSP90-α. These targets are associated with inflammatory signaling, extracellular matrix remodeling, and cell survival pathways. The compound's ability to modulate these diverse targets suggests a multi-faceted mechanism of action in reducing inflammation and protecting cells from oxidative stress-induced damage.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that regaloside C has cardiomyocyte protective activity by protecting mitochondria in H2O2-induced heart H9C2 cells. The compound exhibits antioxidant properties by scavenging ABTS and DPPH free radicals. Its anti-inflammatory activity has been confirmed through various in vitro models, where it reduces the production of pro-inflammatory cytokines and modulates inflammatory signaling pathways.
|
| ln Vivo |
In vivo activity data for regaloside C are limited, as most studies have focused on its in vitro properties. The compound's anti-inflammatory effects observed in vitro suggest potential in vivo applications for inflammatory diseases. Its cardiomyocyte protective activity indicates possible cardiovascular benefits. However, comprehensive in vivo studies in animal models are needed to fully characterize its therapeutic potential and pharmacological effects in living systems.
|
| Enzyme Assay |
Non-cellular assays for regaloside C typically involve antioxidant activity measurements using ABTS and DPPH free radical scavenging assays. These cell-free systems quantify the compound's ability to neutralize free radicals by measuring the reduction in absorbance at specific wavelengths. The compound is incubated with the radical solutions, and the percentage of scavenging activity is calculated. These assays provide a direct measure of the compound's antioxidant capacity without cellular interference.
|
| Cell Assay |
Cellular assays for regaloside C are conducted using H9C2 cardiomyocyte cells exposed to H2O2 to induce oxidative stress. Cells are treated with the compound prior to or simultaneously with H2O2 exposure. Mitochondrial protection is assessed using MTT assays for cell viability, JC-1 staining for mitochondrial membrane potential, and measurement of reactive oxygen species (ROS) levels. Anti-inflammatory activity is evaluated in immune cell lines by measuring cytokine production.
|
| Animal Protocol |
In vivo animal experiments for regaloside C have not been extensively reported in the literature. The compound is primarily studied in vitro for its anti-inflammatory and cardioprotective properties. Future studies may involve rodent models of inflammatory diseases or cardiac injury to evaluate the compound's therapeutic potential. Typical protocols would involve oral or intraperitoneal administration followed by assessment of inflammatory markers, tissue histology, and functional outcomes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for regaloside C are not well-characterized. The compound is soluble in DMSO (100 mg/mL) and is typically stored at -20°C. As a glycoside with molecular weight 416.38 g/mol, it may have limited oral bioavailability due to poor membrane permeability and potential first-pass metabolism. Its stability in biological fluids and plasma protein binding have not been extensively studied. Further pharmacokinetic investigations are needed to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Toxicological data for regaloside C are limited, though as a natural product from edible plants (Lilium bulbs), it is generally considered to have low toxicity. The compound has been used in traditional medicine contexts without significant safety concerns. However, comprehensive toxicological studies including acute and chronic toxicity assessments have not been published. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
Regaloside C has been reported to be found in leopard lilies, lilies of Henry, and other organisms with available data.
Regaloside C is a natural product research compound with no approved clinical indications. It is valuable for studying anti-inflammatory mechanisms, particularly through its modulation of TNF-α, TLR4, and other inflammatory pathways. The compound also serves as a tool for investigating mitochondrial protection and antioxidant defense mechanisms in cardiomyocytes. It may provide insights into therapeutic approaches for managing chronic inflammation and cardiovascular diseases. |
| Molecular Formula |
C18H24O11
|
|---|---|
| Molecular Weight |
416.38
|
| Exact Mass |
416.132
|
| CAS # |
117591-85-2
|
| PubChem CID |
14135348
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.59±0.1 g/cm3
|
| LogP |
-1.4
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
29
|
| Complexity |
542
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C1=CC(=C(C=C1/C=C/C(=O)OC[C@H](CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O
|
| InChi Key |
DVLNCWXFKKSRQB-NSVVQGBUSA-N
|
| InChi Code |
InChI=1S/C18H24O11/c19-6-13-15(24)16(25)17(26)18(29-13)28-8-10(20)7-27-14(23)4-2-9-1-3-11(21)12(22)5-9/h1-5,10,13,15-22,24-26H,6-8H2/b4-2+/t10-,13-,15-,16+,17-,18-/m1/s1
|
| Chemical Name |
[(2S)-2-hydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (240.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4017 mL | 12.0083 mL | 24.0165 mL | |
| 5 mM | 0.4803 mL | 2.4017 mL | 4.8033 mL | |
| 10 mM | 0.2402 mL | 1.2008 mL | 2.4017 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
